The grant will be used to further development of the existing preclinical research collaboration of the two companies.
PCI Biotech and Ultimovacs are both companies in the Radium Hospital Research Foundation´s portfolio and situated in the Oslo Cancer Cluster Innovation Park, above, in co-localisation with the Foundation.
In our podcast Radium we have interviewed both Per Walday, CEO of PCI Biotech and Øyvind Kongstun Arnesen, CEO of Ultimovacs.
The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies and the grant will support these activities.
The Innovation Norway grant of NOK 500,000 is awarded for 2017 and the grant is made available through Oslo Cancer Cluster, a Norwegian Centre of Expertise.
Per Walday, CEO of PCI Biotech, said: “It is very encouraging that Innovation Norway acknowledges the potential in this promising industry and support collaboration initiatives within the Oslo Cancer Cluster, which lie at the heart of the cluster philosophy. We look forward to continue and further strengthen our efforts in this exciting collaboration, exploring synergies between our fimaVACC
technology and Ultimovacs peptide vaccine.“
Øyvind Kongstun Arnesen, CEO of Ultimovacs, commented: “Most early stage life science companies are based on one single technology. Exploring possible synergies in combining these technologies must be done through cooperation between companies. We are very pleased that Innovation Norway sees this point and supports this project.”
Ketil Wideberg, CEO of Oslo Cancer Cluster, commented: “Oslo Cancer Cluster encourages collaboration between companies and are happy to facilitate funding of this exiting project of PCI Biotech and Ultimovacs.”